UCB (OTCMKTS:UCBJY) Sets New 1-Year High – Here’s Why

Shares of UCB SA (OTCMKTS:UCBJY) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $159.31 and last traded at $157.30, with a volume of 19795 shares traded. The stock had previously closed at $153.55.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Jefferies Financial Group upgraded UCB to a “moderate sell” rating in a research report on Sunday, October 26th. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

UCB Stock Up 2.4%

The company has a debt-to-equity ratio of 0.29, a current ratio of 1.35 and a quick ratio of 1.01. The business has a 50-day moving average of $144.89 and a 200-day moving average of $132.16.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.